Back to Screener

BOSTON SCIENTIFIC CORPORATION (BSX)

NYSE Large Cap

Healthcare › Surgical & Medical Instruments & Apparatus

$69.13
Market Cap: $102.6B
Data as of Sep 30, 2025 (TTM)

Price History

Feb 9, 2026 — Apr 4, 2026

Investment Snapshot

  • Trading 168% above Graham Number — above intrinsic value estimate
  • Piotroski F-Score 8/9 — financially strong with improving fundamentals
  • ROE of 11.1% — below-average profitability
  • Revenue growing at 20% annually

BOSTON SCIENTIFIC CORPORATION (BSX) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NYSE , with a market capitalisation of $102.6 billion . Key value metrics: P/E ratio 38.1, P/B ratio 4.23, Piotroski F-Score 8 out of 9 (strong financial health) .

Value Score

Key Metrics

P/E Ratio
38.06
4.23
EPS
$1.82
Div. Yield
PEG Ratio
P/S Ratio
EV/EBITDA
ROE
ROA
Gross Margin
Op. Margin
Net Margin
Debt/Equity
Current Ratio

Current vs 5-Year Average

Based on 5 years of SEC filings
Net Margin
↑ +2.1pp avg —
Gross Margin
↑ +2.1pp avg —
Operating Margin
↑ +2.1pp avg —
Return on Equity
↑ +2.1pp avg —
Debt / Equity
↑ +2.1pp avg —

Revenue & Net Income

EPS & Free Cash Flow Per Share

Financial Statements

Metric FY22 FY23 FY24
Revenue $X.XB $X.XB $X.XB
Gross Profit $X.XB $X.XB $X.XB
Operating Income $X.XB $X.XB $X.XB
Net Income $X.XB $X.XB $X.XB
EBITDA $X.XB $X.XB $X.XB
Total Assets $X.XB $X.XB $X.XB
Total Liabilities $X.XB $X.XB $X.XB
Data sourced from SEC EDGAR and Polygon.io. Methodology. View more Healthcare stocks →

BOSTON SCIENTIFIC CORPORATION — Fundamental Analysis Summary

BOSTON SCIENTIFIC CORPORATION (BSX) is currently trading 168% above its Graham Number of $25.83, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 38.1x.

On financial health, BSX shows a strong Piotroski F-Score of 8/9, indicating improving fundamentals across profitability, leverage, and efficiency, and modest return on equity of 11.1% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.48.

StockPik's composite Value Score for BSX is 72/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

BSX reports a high gross margin of 68.8% (sector average: 33.5%) and a solid operating margin of 18.5%.

BSX shows revenue growing at 20% year-over-year, with earnings growing at 56%.

Top Value Stocks in Healthcare

Symbol Price P/E Score
CYRX $8.21 4.7 100
CRMD $6.70 3.6 100
CGEN $2.06 5.5 100
ABEO $4.82 4.5 100
BDMD $2.01 5.8 100
High Piotroski F-Score stocks
Other stocks with F-Score ≥ 7 showing broad financial improvement
How is the Value Score calculated?
Read our full methodology →
How is the Graham Number calculated?
Benjamin Graham's intrinsic value formula, worked examples, and how to use it →
Previous
BSVN
Next
BSY